EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study

Dawei Huang iD, Jiajing Lu, Fei Tan

Dermatitis® · 2024

DOI: 10.1089/derm.2023.0132 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Dermatitis®, 2024. Verfasst von Dawei Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsPyrimidinesSulfonamidesAdultHumansChinaDouble-Blind MethodProspective StudiesPruritusSeverity of Illness IndexTreatment Outcome

Substanzen

abrocitinibAntibodies, Monoclonal, HumanizeddupilumabHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsPyrimidinesSulfonamidesupadacitinib

Autor:innen und Institutionen

  • From the Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China.
  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
  • Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Dawei Huang

Zitieren

APA

Huang, D., Lu, J., & Tan, F. (2024). Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study. Dermatitis®. https://doi.org/10.1089/derm.2023.0132

Vancouver

Huang D, Lu J, Tan F. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study. Dermatitis®. 2024. doi:10.1089/derm.2023.0132

BibTeX
@article{Huang2024,
  author = {Huang, Dawei and Lu, Jiajing and Tan, Fei},
  title = {Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study},
  journal = {Dermatitis®},
  year = {2024},
  doi = {10.1089/derm.2023.0132}
}
Kostenlos starten →